Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca’s Faslodex approved for advanced breast cancer in Europe

AstraZeneca’s Faslodex approved for advanced breast cancer in Europe

28th July 2017

AstraZeneca has announced that its drug Faslodex has been approved as a treatment for advanced breast cancer by the European Commission.

The drug has been ratified for use as a treatment for oestrogen-receptor positive, locally-advanced or metastatic breast cancer in postmenopausal women who have not previously been treated with endocrine therapy.

This approval was based on positive data from the phase III FALCON trial, which demonstrated the superior performance of Faslodex as a first-line treatment for postmenopausal women compared to another therapy.

Faslodex is the only hormonal medicine for advanced breast cancer that has been shown to slow tumour growth by binding to and degrading the oestrogen receptor – a key driver of breast cancer progression in many women.

Jamie Freedman, executive vice-president and head of AstraZeneca's oncology business unit, said: "We continue to explore the full potential of this important medicine as monotherapy and in combination with other medicines."

The therapy was first approved in 2002 and is currently being tested in combination with more than 19 different medicines for the treatment of breast cancer.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801838382-ADNFCR

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.